Fig. 1 · Structure

Documents & Downloads

Rimonabant hydrochloride

Cat. No. A11548 CAS 158681-13-1

CB1 receptor inverse agonist

Rimonabant hydrochloride is a CB1 receptor inverse agonist.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
CB1 Ki 1.8 nM

Cellular Effect

Cell Line Activity Value Description Reference
BV-2 IC50 16.17 μM Inhibition of LPS-induced NO production in mouse BV-2 cells incubated for 24 hrs by Griess reagent based method [PMID: 36371018]
CHO IC50 0.004 μM Antagonist activity at CB1 receptor transfected in CHO cells expressing apoaequorin as a reporter for G-protein-coupled receptor-mediated calcium signaling by bioluminescence assay [PMID: 21376588]
CHO IC50 0.0135 μM Antagonist activity against CB1R (unknown origin) CHO cells stably expressing Galpha16 assessed as inhibition of CP55940-induced increase in intracellular calcium level pre-treated 10 mins before CP55940 stimulation by microplate reader based assay [PMID: 26151231]
CHO EC50 0.11 nM Inverse agonist activity at human cannabinoid CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation after 60 mins [PMID: 20047779]
CHO IC50 1.98 μM Displacement of [3H]CP55940 from human cannabinoid CB2 receptor expressed in CHO cells at pH 7.4 after 1 hr by liquid scintillation counting [PMID: 21741835]
CHO EC50 10.1 μM Agonist activity at human GPR18 expressed in CHO cells assessed as induction of beta-arrestin recruitment by beta-galactosidase enzyme fragment complementation method 10.1039/C3MD00394A
CHO IC50 10.1 μM Antagonist activity at human GPR18 transfected in CHO cells assessed as delta9-THC-induced beta-arrestin recruitment incubated 60 mins prior to delta9-THC addition by beta-arrestin translocation assay [PMID: 23679955]
CHO IC50 108 nM Inverse agonist activity at human recombinant CB1 receptor expressed in CHO cells by luciferase reporter gene assay [PMID: 20045337]
CHO IC50 13 nM Antagonist activity at human CB1 receptor stably expressed in CHO cells co-expressing co-expressing Ga15/16 assessed as calcium current after 45 mins by fluo-4 AM assay [PMID: 24445310]
CHO EC50 2.01 μM Agonist activity at GPR55 (unknown origin) expressed in CHO cells assessed as inhibition of LPI-induced beta-arrestin translocation after 90 mins by luminescence assay [PMID: 24900561]
CHO EC50 2.01 μM Agonist activity at human GPR55 expressed in CHO cells assessed as induction of LPI-induced beta-arrestin recruitment by beta-galactosidase enzyme fragment complementation method 10.1039/C3MD00394A
CHO IC50 3.2 nM Antagonist activity at human cannabinoid CB1 receptor expressed in CHO cells coexpressing Galpha15/16 assessed as inhibition of CP-55940-induced Ca2+ release after 10 mins by micro plate reader [PMID: 20047779]
CHO EC50 5 nM Inverse agonist activity at human CB1 receptor expressed in CHO cells assessed as increase in intracellular calcium mobilization after 90 secs by Calcein-4 AM-staining based FLIPR assay [PMID: 26827137]
CHO IC50 9.1 μM Antagonist activity against CB2R (unknown origin) CHO cells stably expressing Galpha16 assessed as inhibition of CP55940-induced increase in intracellular calcium level pre-treated 10 mins before CP55940 stimulation by microplate reader based assay [PMID: 26151231]
CHO IC50 92.5 nM Binding affinity to human CB2 receptor expressed in CHO cells by luciferase reporter gene assay [PMID: 19850473]
CHO IC50 9800 nM Antagonist activity at CB2 receptor (unknown origin) stably expressed in CHO cells co-expressing co-expressing Ga15/16 assessed as calcium current after 45 mins by fluo-4 AM assay [PMID: 24445310]
CHO-K1 IC50 > 1000 nM Displacement of [3H]WIN-55212-2 from human CB2 receptor expressed in CHO-K1 cells by liquid scintillation counting [PMID: 19128970]
CHO-K1 IC50 120 nM Antagonist activity at human CB1 receptor expressed in CHOK1 cells by luciferase assay [PMID: 18243711]

18 records · Scroll to view more

Rimonabant hydrochloride Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of Rimonabant hydrochloride from 2 published references. In vitro models include MDA-MB-231 cells.

Rimonabant hydrochloride In Vitro Studies

MDA-MB-231 cells were exposed to Rimonabant at 10 μM for 48 h, with untreated cells as controls. Rimonabant itself did not exert a GSH-depleting effect. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

GSH response in breast cancer cells

Cell-based study · MDA-MB-231 cells [1]

MDA-MB-231 cells were treated with Rimonabant at 10 μM for 48 h and compared with untreated controls. Rimonabant itself did not exert a GSH-depleting effect.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The level of GSHReported result rimonabant itself did not exert GSH-depleting effect[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
48 h
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Rimonabant

The paper names Rimonabant without stating the salt or form; not verified as the hydrochloride form supplied as A11548. No dose conversion or lot validation.

Material and methods > GSH measurements (S60); Results > Rimonabant combined with erastin/RSL3 significantly inhibited TNBC cell growth by inducing ferroptosis and cell cycle arrest (S158, S166)

The level of GSH: The level of GSH; comparator: untreated controls — Results > Rimonabant combined with erastin/RSL3 significantly inhibited TNBC cell growth by inducing ferroptosis and cell cycle arrest (S158, S166)

Rimonabant hydrochloride In Vivo Studies

Ts65Dn mice received Rimonabant through drinking water, reaching a final dose of 0.5 mg/kg/day. At 10 months of age, treated male and female mice showed memory improvement assessed by the discrimination index in NORT. In a separate analysis at 10 months of age, dorsal hippocampal CB1R protein levels did not differ between vehicle- and Rimonabant-treated Ts65Dn mice. [2]

Memory improvement in male and female Ts65Dn mice

Animal study · Ts65Dn male (C) and female (D) mice; males: Ts65Dn VEH n = 6; Ts65Dn RIM n = 12; females: Ts65Dn VEH n = 10; Ts65Dn RIM n = 9 [2]

Male and female Ts65Dn mice received Rimonabant through drinking water, reaching a final dose of 0.5 mg/kg/day. At 10 months of age, memory improvement was observed in treated males and females, assessed by the discrimination index in NORT.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Discrimination index in NORTReported result 0.5 mg/kg/day; 10 months of age: memory improvement was again observed in rimonabant‐treated male and female Ts65Dn mice.[2]

Conditions shared by the study groups

Route
through the drinking water
Treatment course
from PND21 until 10 months of age; During the first 2.5 months of treatment mice received rimonabant 0.1 mg/kg/day. This dose was increased to the final concentration of 0.5 mg/kg/day by 3.5 months of age.
Vehicle
0.3% 2‐hydroxypropyl‐β‐cyclodextrin in water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Rimonabant 0.1 mg/kg/day; 0.5 mg/kg/dayTs65Dn VEH0.5 mg/kg/day; 10 months of age: memory improvement was again observed in rimonabant‐treated male and female Ts65Dn mice.[2]
Rimonabant 0.1 mg/kg/day; 0.5 mg/kg/day
Model: Ts65Dn male (C) and female (D) mice; males: Ts65Dn VEH n = 6; Ts65Dn RIM n = 12; females: Ts65Dn VEH n = 10; Ts65Dn RIM n = 9
Methods and source locations

Compound reported in the paper: Rimonabant

The paper names Rimonabant without stating the salt or form; not verified as the hydrochloride form supplied as A11548. No dose conversion or lot validation.

METHODS > Drug treatments (S44, S48, S49); RESULTS > Sustained oral administration of a low dose of rimonabant improves memory performance in young‐adult and middle‐aged Ts65Dn mice (S137, S144); FIGURE 2 legend (S190)

Discrimination index in NORT: Discrimination index in NORT; comparator: Ts65Dn VEH — RESULTS > Sustained oral administration of a low dose of rimonabant improves memory performance in young‐adult and middle‐aged Ts65Dn mice (S144); FIGURE 2 legend (S190)

Rimonabant 0.1 mg/kg/day; 0.5 mg/kg/day · METHODS > Drug treatments (S48, S49); RESULTS > Sustained oral administration of a low dose of rimonabant improves memory performance in young‐adult and middle‐aged Ts65Dn mice (S137, S144); FIGURE 2 legend (S190)

Hippocampal CB1R protein levels in Ts65Dn mice

Animal study · Ts65Dn mice; 10 months of age; Ts65Dn VEH, n = 4, Ts65Dn RIM, n = 6 [2]

Ts65Dn mice received Rimonabant through drinking water, reaching a final dose of 0.5 mg/kg/day. At 10 months of age, dorsal hippocampal western blot analysis showed no difference in CB1R protein levels between vehicle- and Rimonabant-treated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
western blot analysis in the dorsal hippocampus of mice at 10 months of ageReported result 0.5 mg/kg/day; 10 months of age: CB1R protein levels did not differ between vehicle‐ and rimonabant‐treated Ts65Dn mice.[2]

Conditions shared by the study groups

Route
through the drinking water
Treatment course
from PND21 until 10 months of age; During the first 2.5 months of treatment mice received rimonabant 0.1 mg/kg/day. This dose was increased to the final concentration of 0.5 mg/kg/day by 3.5 months of age.
Vehicle
0.3% 2‐hydroxypropyl‐β‐cyclodextrin in water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Rimonabant 0.1 mg/kg/day; 0.5 mg/kg/dayTs65Dn mice treated with vehicle0.5 mg/kg/day; 10 months of age: CB1R protein levels did not differ between vehicle‐ and rimonabant‐treated Ts65Dn mice.[2]
Rimonabant 0.1 mg/kg/day; 0.5 mg/kg/day
Model: Ts65Dn mice; 10 months of age; Ts65Dn VEH, n = 4, Ts65Dn RIM, n = 6
Methods and source locations

Compound reported in the paper: Rimonabant

The paper names Rimonabant without stating the salt or form; not verified as the hydrochloride form supplied as A11548. No dose conversion or lot validation.

METHODS > Drug treatments (S44, S48, S49); RESULTS > Sustained oral administration of a low dose of rimonabant improves memory performance in young‐adult and middle‐aged Ts65Dn mice (S137, S152, S154); FIGURE 2 legend (S192)

western blot analysis in the dorsal hippocampus of mice at 10 months of age: western blot analysis in the dorsal hippocampus of mice at 10 months of age; comparator: Ts65Dn mice treated with vehicle — RESULTS > Sustained oral administration of a low dose of rimonabant improves memory performance in young‐adult and middle‐aged Ts65Dn mice (S152, S154); FIGURE 2 legend (S192)

Rimonabant 0.1 mg/kg/day; 0.5 mg/kg/day · METHODS > Drug treatments (S48, S49); RESULTS > Sustained oral administration of a low dose of rimonabant improves memory performance in young‐adult and middle‐aged Ts65Dn mice (S137, S154); FIGURE 2 legend (S192)

Specifications

Manufacturer Adooq Bioscience
Actions Inverse Agonist
CAS Number 158681-13-1
Applications CB1 receptor inverse agonist
Formula C22H22Cl4N4O
Molecular Weight 500.25
Synonyms SR 141716A; SR 151716A
SMILES
CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Rimonabant hydrochloride Research References

  1. [1] Li P, Lin Q, Sun S, et al. Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism. Cell Death Dis (2022). PMID: 36130940 DOI: 10.1038/s41419-022-05242-5 Source material
  2. [2] Vázquez-Oliver A, Pérez-García S, Romero-Pérez R, et al. Targeting dysregulated CB1 receptors in a Down syndrome mouse model improves neurological outcomes. Alzheimers Dement (2025). PMID: 41257439 DOI: 10.1002/alz.70874 Source material

Added to your cart

View Cart Checkout
Loading...